165 related articles for article (PubMed ID: 35786377)
1. Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients.
Spyropoulos AC
Expert Rev Hematol; 2022 Jul; 15(7):597-605. PubMed ID: 35786377
[TBL] [Abstract][Full Text] [Related]
2. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
Spyropoulos AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective.
Spyropoulos AC; Ageno W; Cohen AT; Gibson CM; Goldhaber SZ; Raskob G
Thromb Haemost; 2020 Jun; 120(6):924-936. PubMed ID: 32492724
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.
MacDougall K; Spyropoulos AC
Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
[TBL] [Abstract][Full Text] [Related]
6. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
7. Eligibility for Posthospitalization Venous Thromboembolism Prophylaxis in Hospitalized Patients With COVID-19: A Retrospective Cohort Study.
Vaughn VM; Ratz D; McLaughlin ES; Horowitz JK; Flanders SA; Middleton EA; Grant PJ; Kaatz S; Barnes GD
J Am Heart Assoc; 2022 Oct; 11(19):e025914. PubMed ID: 36073649
[TBL] [Abstract][Full Text] [Related]
8. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
9. Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports.
Kyriakoulis KG; Kollias A; Kyriakoulis IG; Kyprianou IA; Papachrysostomou C; Makaronis P; Kotronias RA; Terentes-Printzios D; Toskas I; Mikhailidis DP
Curr Vasc Pharmacol; 2022; 20(1):96-110. PubMed ID: 34431465
[TBL] [Abstract][Full Text] [Related]
10. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
11. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
[TBL] [Abstract][Full Text] [Related]
12. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
[TBL] [Abstract][Full Text] [Related]
13. Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis.
Mehrabi F; Farshbafnadi M; Rezaei N
Clin Appl Thromb Hemost; 2023; 29():10760296221148477. PubMed ID: 36596272
[TBL] [Abstract][Full Text] [Related]
14. New paradigms in venous thromboprophylaxis of medically ill patients.
Spyropoulos AC; Raskob GE
Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
[TBL] [Abstract][Full Text] [Related]
15. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulants for extended-duration thromboprophylaxis in hospitalized medically ill patients: are we there yet?
Al Yami MS; Alfayez OM; Kurdi SM; Alsheikh R
J Thromb Thrombolysis; 2017 Jul; 44(1):1-8. PubMed ID: 28197755
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.
Mahan CE; Fisher MD; Mills RM; Fields LE; Stephenson JJ; Fu AC; Spyropoulos AC
Thromb Res; 2013 Nov; 132(5):520-6. PubMed ID: 24080150
[TBL] [Abstract][Full Text] [Related]
18. Proportion of US Hospitalized Medically Ill Patients Who May Qualify for Extended Thromboprophylaxis.
Miao B; Chalupadi B; Clark B; Descoteaux A; Huang D; Ilham S; Ly B; Spyropoulos AC; Coleman CI
Clin Appl Thromb Hemost; 2019; 25():1076029619850897. PubMed ID: 31088302
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection.
Quiros Ambel H; Crespo-Robledo P; Arribalzaga Juaristi K; Plo-Seco I; Martínez Simón JJ; Pérez Fernández E; Perez Encinas M
Eur J Hosp Pharm; 2023 Sep; 30(5):264-267. PubMed ID: 34649964
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
